Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillaume Cartron

Showing results (1-10 of 239) with videos related to

Pageof 24
Sort By:
Leukemia & Lymphoma|August 13, 2009
FCGR3A polymorphism story: a new piece of the puzzleGuillaume Cartron
Haematologica|January 5, 2022
Time for an individualized approach to first-line management of follicular lymphomaGuillaume Cartron, Judith Trotman
Blood|June 7, 2017
Obinutuzumab: what is there to learn from clinical trials?Guillaume Cartron, Hervé Watier
La Revue Du Praticien|October 23, 2025
[Bispecific antibodies: indications and perspectives in onco-hematology]Léa Fornero, Guillaume Cartron
Therapeutic Advances in Hematology|April 8, 2016
Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomasLudovic Gabellier, Guillaume Cartron
Expert Review of Clinical Immunology|December 25, 2018
Infusion-related reactions to rituximab: frequency, mechanisms and predictorsFranciane Paul, Guillaume Cartron
Leukemia & Lymphoma|June 6, 2014
New anti-CD20 monoclonal antibodies: which is the best?Anne-Laure Gagez, Guillaume Cartron
Current Opinion in Oncology|July 12, 2014
Obinutuzumab: a new class of anti-CD20 monoclonal antibodyAnne-Laure Gagez, Guillaume Cartron
Medecine Sciences : M/S|December 29, 2009
[Therapeutic monoclonal antibodies in onco-hematology]Guillaume Cartron, Jean-François Rossi
Current Opinion in Oncology|September 1, 2007
Maintenance therapy for low-grade lymphomas: has the time come?Guillaume Cartron, Philippe Solal-Céligny
Pageof 24

Showing results (1-10 of 239) with videos related to

Sort By:
Pageof 24
Leukemia & Lymphoma|August 13, 2009
FCGR3A polymorphism story: a new piece of the puzzleGuillaume Cartron
Haematologica|January 5, 2022
Time for an individualized approach to first-line management of follicular lymphomaGuillaume Cartron, Judith Trotman
Blood|June 7, 2017
Obinutuzumab: what is there to learn from clinical trials?Guillaume Cartron, Hervé Watier
La Revue Du Praticien|October 23, 2025
[Bispecific antibodies: indications and perspectives in onco-hematology]Léa Fornero, Guillaume Cartron
Therapeutic Advances in Hematology|April 8, 2016
Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomasLudovic Gabellier, Guillaume Cartron
Expert Review of Clinical Immunology|December 25, 2018
Infusion-related reactions to rituximab: frequency, mechanisms and predictorsFranciane Paul, Guillaume Cartron
Leukemia & Lymphoma|June 6, 2014
New anti-CD20 monoclonal antibodies: which is the best?Anne-Laure Gagez, Guillaume Cartron
Current Opinion in Oncology|July 12, 2014
Obinutuzumab: a new class of anti-CD20 monoclonal antibodyAnne-Laure Gagez, Guillaume Cartron
Medecine Sciences : M/S|December 29, 2009
[Therapeutic monoclonal antibodies in onco-hematology]Guillaume Cartron, Jean-François Rossi
Current Opinion in Oncology|September 1, 2007
Maintenance therapy for low-grade lymphomas: has the time come?Guillaume Cartron, Philippe Solal-Céligny
Pageof 24